Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 79
Filter
1.
J Chromatogr B Biomed Sci Appl ; 759(1): 99-108, 2001 Aug 05.
Article in English | MEDLINE | ID: mdl-11499634

ABSTRACT

CGS 26214 is a synthetic cholesterol-lowering agent shown to be active in the rat, dog and monkey. The present work was conducted to develop a sensitive liquid chromatography-tandem mass spectrometry (LC-MS-MS) method for quantitative determination of the compound in human plasma following clinical doses of 10-100 microg per day. A number of analytical challenges were encountered during the development of the assay. The compound was an ester and susceptible to hydrolysis under experimental conditions. A lower limit of quantitation of 50 pg/ml was needed due to the low clinical doses. Positive electrospray ionization of CGS 26214 yielded insufficient sensitivity needed for the studies. Consequently, LC-MS-MS conditions were optimized for the negative ion mode of detection. The sample preparation steps proved to be critical in order to reduce the possibility of microbore column (50 mm x 1.0 mm I.D.) obstruction, chromatographic deterioration, and matrix mediated electrospray ion suppression. The present method addressed the above issues. The method was accurate and reproducible and was successfully applied to generate plasma concentration-time profiles for human subjects after low oral doses of the compound.


Subject(s)
Anticholesteremic Agents/blood , Glyoxylates/blood , Mass Spectrometry/methods , Calibration , Humans , Reproducibility of Results , Sensitivity and Specificity
2.
Rapid Commun Mass Spectrom ; 15(12): 898-907, 2001.
Article in English | MEDLINE | ID: mdl-11400194

ABSTRACT

A semi-automated high-throughput liquid/liquid extraction (LLE) assay was developed for RAD001 and cyclosporin A (CsA) in human blood. After addition of internal standard and ammonium hydroxide, samples were extracted twice with methyl tert-butyl ether (MTBE). The organic extract was evaporated to dryness and reconstituted in mobile phase. Where possible, sample transfer and LLE steps were automated using a Tomtec Quadra 96 workstation. Samples were analyzed using ESI-LC/MS/MS employing the transitions of ([M + NH(4)](+) --> [M + H](+)) for CsA and ([M + NH(4)](+) --> [M + H-(CH(3)OH + H(2)O)](+)) for RAD001, under isocratic chromatographic conditions (75:25, (v/v), acetonitrile/20 mM ammonium acetate) with a run time of 3.6 min. A lower limit of quantitation (LLOQ) of 0.368 ng/mL and 5.23 ng/mL was achieved for RAD001 and CsA, respectively, using a sample volume of 0.3 mL for the analysis. The method was validated over a 3-day period and the resulting calibration curves had a correlation coefficient >0.99 over the concentration range 0.368 to 409 ng/mL and 5.24 to 1748 ng/mL for RAD001 and CsA, respectively. The inter-day coefficient of variation (CV) was less than 15% at the LLOQ for both compounds. The method was applied to the analysis of clinical samples. Under normal working conditions four 96-well plates could be extracted and LC/MS analysis completed in less than 28 h. A marked improvement in sample throughput efficiency was realized with this LLE method when compared to existing solid phase extraction (SPE) methods which deal with both RAD001 and CsA.


Subject(s)
Chromatography, Liquid/methods , Cyclosporine/blood , Gas Chromatography-Mass Spectrometry/methods , Immunosuppressive Agents/blood , Sirolimus/blood , Drug Therapy, Combination , Everolimus , Gas Chromatography-Mass Spectrometry/instrumentation , Humans , Reproducibility of Results , Sensitivity and Specificity , Sirolimus/analogs & derivatives , Time Factors
4.
Chirality ; 13(2): 63-74, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11170248

ABSTRACT

Recent advances in mass spectrometry have rendered it an attractive and versatile tool in industrial and academic research laboratories. As a part of this rapid growth, a considerable body of literature has been devoted to the application of mass spectrometry in studies involving enantioselectivity, molecular recognition, and supramolecular chemistry. In concert with separation techniques such as capillary electrophoresis and liquid chromatography, mass spectrometry allows rapid characterization of a large array of molecules in complex mixtures. A majority of these findings have been made possible by the introduction of 'soft-ionization' techniques such as electrospray ionization interface. Other techniques such as atmospheric pressure chemical ionization mass spectrometry have been widely used as a rugged interface for quantitative liquid chromatography-mass spectrometry. Herein, we present a brief overview of the above techniques accompanied with several examples of enantioselective capillary electrophoresis- and liquid chromatography-mass spectrometry in drug discovery and development. Although the emphasis of this article is on quantitative enantiomeric chromatography-mass spectrometry, we envisage that similar strategies are adaptable in qualitative studies.


Subject(s)
Chromatography, Liquid/methods , Mass Spectrometry/methods , Atmospheric Pressure , Humans , Stereoisomerism
5.
Rapid Commun Mass Spectrom ; 14(23): 2282-93, 2000.
Article in English | MEDLINE | ID: mdl-11114039

ABSTRACT

Ketoconazole, an imidazole-piperazine compound, is an orally active antimycotic agent. In addition, ketoconazole is a specific inhibitor of cytochrome P450 3A4. As about 60% of oxidized drugs are biotransformed by this isoform, the potential effect of a concomitant administration of ketoconazole on drug disposition may be of interest during drug development. The present paper describes three different approaches (methods A, B, and C) to attain high-throughput sample preparation and analysis in the quantification of ketoconazole in human plasma. Method A consisted of acetonitrile precipitation in a 96-well plate, transfer of the supernatant via a Tomtec Quadra 96 Model 320, and subsequent injection onto a 50 x 4.6 mm (i.d.) Develosil Combi-RP-5 column (packed with C30 bonded silica particles). Method B consisted of an identical sample preparation to method A with the exception that a Michrom Magic Bullet(trade mark) column, 2.0 --> 0.50 mm (i.d., tapered bore) x25 mm length, was used. Lastly, in method C, a turbulent-flow chromatography (TurboFlow LC/APCI-MS/MS) module was used for the direct analysis of ketoconazole in human plasma. A Sciex API 3000 was used in methods A and B, while a Micromass Quattro LC was employed in method C. Based on the values obtained for the calibrator (standard) and quality control samples, all three protocols yielded satisfactory accuracy, precision, and reduced manual sample preparation time.


Subject(s)
Antifungal Agents/blood , Chemistry Techniques, Analytical/methods , Cytochrome P-450 Enzyme Inhibitors , Enzyme Inhibitors/blood , Ketoconazole/blood , Mixed Function Oxygenases/antagonists & inhibitors , Chromatography, Liquid , Cytochrome P-450 CYP3A , Humans , Mass Spectrometry , Reproducibility of Results , Time Factors
6.
Rapid Commun Mass Spectrom ; 14(21): 1965-71, 2000.
Article in English | MEDLINE | ID: mdl-11085405

ABSTRACT

A semi-automated solid-phase extraction (SPE) liquid chromatography/mass spectrometry (LC/MS) procedure was validated for the simultaneous determination of everolimus (RAD001) and cyclosporin A (CsA) in human blood. Whole blood samples (350microL) were pretreated with acetonitrile/zinc sulfate mixture to precipitate the sample proteins. The samples were centrifuged and the resulting supernatants were manually transferred to a 96-well plate format. All subsequent sample transfer and solid phase extraction was automated using a Tomtec Quadra 96 workstation. Samples were analyzed by LC/MS using an atmospheric pressure chemical ionization (APcI) interface. In order to enhance sensitivity, the MS method used negative ion mode for RAD001 ([M]-) and its internal standard and positive ion mode for CsA ([M + H]+) and its internal standard. The lower limit of quantitation was 0.375 ng.ml(-1) for RAD001 and 6.95 ng.ml(-1) for CsA. The reproducibility of the method was evaluated by analyzing six replicates at five or more quality control (QC) levels over the nominal concentration range 0.375 to 253 ng.ml(-1) for RAD001 and 6.95 to 1,530 ng.ml(-1) for CsA. The inter- and intra-day accuracy was found to range from 89.7 to 114% with precision (% CV) of less than 12% for both compounds. The sensitivity, small sample volume needed and high sample throughput of this method make it an attractive option for pharmacokinetic studies in pediatric patients.


Subject(s)
Chromatography, Liquid/methods , Cyclosporine/blood , Mass Spectrometry/methods , Sirolimus/analogs & derivatives , Automation/instrumentation , Automation/methods , Calibration , Chromatography, Liquid/instrumentation , Cyclosporine/chemistry , Everolimus , Humans , Immunosuppressive Agents/blood , Immunosuppressive Agents/chemistry , Kidney Transplantation/immunology , Mass Spectrometry/instrumentation , Molecular Structure , Quality Control , Reference Standards , Reproducibility of Results , Sensitivity and Specificity , Sirolimus/blood , Sirolimus/chemistry
7.
J Pharm Biomed Anal ; 23(4): 745-55, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10975250

ABSTRACT

CGS 26214 is a racemic compound having cholesterol-lowering activity in rats, dogs, and monkeys. This compound has two equipotent chiral components CGS 28934(-) and CGS 28935(+). An analytical challenge was to develop a sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the analysis of the chiral components in human plasma following clinical doses of 1 mg or less. Several issues had to be addressed in order to devise a LC/MS/MS assay for the above compounds. First, the compounds were esters and susceptible to hydrolysis under experimental conditions. Second, a lower limit of quantitation (LLOQ) of 0.4 ng/ml was needed. Third, positive electrospray ionization of CGS 26214 did not yield sufficient sensitivity needed for the studies in humans. Consequently, LC/MS/MS conditions were optimized for negative ion mode of detection. Fourth, sample preparation steps proved to be critical in order to reduce the possibility of microbore chiral-HPLC column (100 x 1.0 mm i.d.) obstruction, chromatographic deterioration, and matrix mediated electrospray ion suppression. Although the present method addressed the above challenges, its major drawback was limited sample throughput capability. Nonetheless, the method was successfully applied to generate plasma concentration-time profiles for human subjects after oral doses (0.9 mg) of the racemate as well as the optically pure isomers.


Subject(s)
Glyoxylates/blood , Hypolipidemic Agents/blood , Chromatography, Liquid , Humans , Mass Spectrometry , Quality Control , Reference Standards , Reproducibility of Results , Stereoisomerism
8.
Mutagenesis ; 15(5): 415-30, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10970448

ABSTRACT

Biological polymers undergo numerous significant and fascinating interactions, such as post-translational modifications, non-covalent associations and conformational changes. A valuable parameter for the characterization of a biopolymer is molecular weight. Modern methods of mass spectrometry, including electrospray ionization and matrix-assisted laser desorption ionization mass spectrometry, are ideally suited for the accurate determination of the molecular weight of a biopolymer of interest. Molecular weight measurements are now routinely utilized in the qualitative and quantitative analysis of macromolecules. In many cases small sample quantities (i.e. a few micrograms) limit the utility of nuclear magnetic resonance spectroscopy and X-ray crystallography in obtaining structural information. Thus, mass spectrometry offers an attractive alternative to the more traditional bioanalytical methods for rapid and sensitive measurements. The ultimate goal of these experiments is to obtain sufficient information in order to map the complex molecular circuitry which operates within the cell. In the analysis of complex mixtures mass spectrometry is even more powerful when utilized in conjunction with separation methods. Herein we present some of the aspects of modern biological mass spectrometry for the investigation of large molecules. For more advanced or detailed technical descriptions we refer the reader to a number of recently published reports.


Subject(s)
Spectrometry, Mass, Electrospray Ionization , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Animals , Macromolecular Substances , Molecular Weight , Oligonucleotide Array Sequence Analysis , Peptides/analysis , Polymers/analysis , Protein Processing, Post-Translational , Proteins/analysis
9.
Rapid Commun Mass Spectrom ; 14(14): 1214-9, 2000.
Article in English | MEDLINE | ID: mdl-10918370

ABSTRACT

An analytical method for the determination of terbinafine (Lamisil(R)) in human hair was developed and validated. Human hair (10 mg) was hydrolyzed in 0.50 mL of 5.0 N sodium hydroxide for 1.5 h. The aqueous layer was extracted with 1.5 mL of n-hexane. The organic layer was separated and re-extracted with 0.20 mL of formic acid (12.5%)/2-propanol (85:15, v/v). The aqueous layer was separated and 0.010 mL of the aqueous extract was injected onto a reversed-phase microbore (50 x 1.0 mm i.d.) column for analysis by liquid chromatography/tandem mass spectrometry (LC/MS/MS). The instrument was equipped with an electrospray ionization (ESI) interface and operated in the positive ion mode of detection. Interday and intraday accuracy and precision were assessed from the relative recoveries of spiked samples analyzed on three different days. The method showed excellent specificity and ruggedness with a lower limit of quantitation of 10 ng/g (i.e., 10 ppb) using 10 mg of human hair.


Subject(s)
Antifungal Agents/analysis , Hair , Naphthalenes/analysis , Antifungal Agents/chemistry , Antifungal Agents/pharmacokinetics , Chromatography, Liquid/methods , Humans , Mass Spectrometry/methods , Naphthalenes/chemistry , Naphthalenes/pharmacokinetics , Terbinafine
10.
Rapid Commun Mass Spectrom ; 14(13): 1128-35, 2000.
Article in English | MEDLINE | ID: mdl-10867688

ABSTRACT

Chiral liquid chromatography is a well-established area of bioanalytical chemistry and is often used during the processes of drug discovery and development. The development and use of a chiral drug require the understanding of the pharmacokinetic characteristics of each of the enantiomers, including potential differences in their absorption, distribution, metabolism, and excretion. Chromatographic techniques coupled to atmospheric pressure ionization-tandem mass spectrometry have shown potential as sensitive and robust tools in the quantitative and qualitative determination of enantiomers in biologic fluids and tissue extracts. However, development of a chiral liquid chromatography method requires time-consuming procedures that are devised empirically. Clearly, there is an incentive to design chromatographic approaches that are easy to use, compatible with mass spectrometry ionization interface conditions, exhibit relatively short run times without compromising sensitivity, and offer a broad analyte specificity. For these reasons, the present paper explores the feasibility of the bonded macrocyclic glycopeptide phases (teicoplanin and vancomycin) for analysis by chiral liquid chromatography/tandem mass spectrometry. Ritalinic acid, pindolol, fluoxetine, oxazepam, propranolol, terbutaline, metoprolol, and nicardipine were tested in this study. Furthermore, an example of a simultaneous chiral LC/MS/MS detection (chromatographic run time approximately 10 min) of four pharmaceutical products resulting in baseline resolutions of all four pairs of enantiomers is presented. Methanol, an MS-compatible mobile phase, was utilized in all the experiments.


Subject(s)
Anti-Bacterial Agents/chemistry , Pharmaceutical Preparations/analysis , Teicoplanin/chemistry , Vancomycin/chemistry , Chromatography, Liquid , Mass Spectrometry
11.
Rapid Commun Mass Spectrom ; 14(9): 740-5, 2000.
Article in English | MEDLINE | ID: mdl-10825011

ABSTRACT

Methylphenidate (MPH; Ritalin: methyl-alpha-phenyl-2-piperidinacetate hydrochloride) is utilized for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. Recently, we described a rapid enantioselective liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of the enantiomers of MPH (Rapid Commun. Mass Spectrom. 1999; 13: 2054). A lower limit of quantification (LLOQ) of 87 pg/mL was attained for the human plasma assay. The present paper describes a high-throughput sample preparation procedure in conjunction with racemic LC/MS/MS analysis for MPH with a LLOQ of 50 pg/mL. A semi-automated robotics method using liquid-liquid extraction (LLE) in a 96-well plate format was developed and validated. The correlation coefficients were > or =0.998 for MPH indicating good fits of the regression models over the range of the calibration curve. The accuracy and precision of the semi-automated approach were comparable to those obtained using the manual sample preparation technique reported previously (vide supra). The current method can easily be adapted to the enantioselective LC/MS/MS assay of MPH. The assay was simple, fast, specific, and exhibited excellent ruggedness.


Subject(s)
Methylphenidate/blood , Attention Deficit Disorder with Hyperactivity/blood , Calibration , Chromatography, Liquid/methods , Humans , Mass Spectrometry/methods , Narcolepsy/blood , Regression Analysis , Reproducibility of Results , Robotics , Stereoisomerism
12.
Rapid Commun Mass Spectrom ; 14(6): 476-81, 2000.
Article in English | MEDLINE | ID: mdl-10717659

ABSTRACT

Iralukast (CGP 45715A) is a potent peptido-leukotriene antagonist that is active in various in vitro and animal models for the treatment of asthma. An analytical challenge was to develop a sensitive liquid chromatography/tandem mass spectrometry (LC/MS/MS) method with a lower limit of quantitation (LLOQ) of 10 pg/mL for the analysis of iralukast when administered at low doses during clinical trials. Several issues had to be addressed in order to devise a LC/MS/MS assay for the above compound. First, iralukast appeared to be light sensitive and unstable at room temperature under acidic conditions. Second, a LLOQ of 10 pg/mL was needed to support several clinical trials. Third, positive electrospray ionization of iralukast did not yield the necessary sensitivity required for studies in humans. Consequently, LC/MS/MS conditions were optimized for the negative ion mode of detection. Fourth, sample preparation steps proved to be critical to reduce the possibility of microbore HPLC column (50 mm x 1.0 mm i.d.) obstruction, chromatographic deterioration, and matrix-mediated electrospray ion suppression. While our validated method addressed the above challenges, its major drawback was limited sample throughput capability. Nonetheless, plasma concentration-time profiles for patients with moderate asthma after oral administration of 200, 500, 1000, and 5000 microgram/kg/day of iralukast were successfully obtained.


Subject(s)
Anti-Asthmatic Agents/blood , Benzopyrans/blood , Leukotriene Antagonists/blood , Anti-Asthmatic Agents/pharmacokinetics , Benzopyrans/pharmacokinetics , Calibration , Chromatography, Liquid , Freezing , Humans , Indicators and Reagents , Leukotriene Antagonists/pharmacokinetics , Mass Spectrometry , Quality Control , Reference Standards , Solutions
13.
Rapid Commun Mass Spectrom ; 14(3): 141-9, 2000.
Article in English | MEDLINE | ID: mdl-10637419

ABSTRACT

A method using liquid chromatography/tandem mass spectrometry (LC/MS/MS) for the determination of terbinafine in human and minipig plasma has been developed and validated. The method used positive-ion mode for monitoring terbinafine, and used a stable isotope labelled terbinafine as the internal standard. Subsequent to acetonitrile protein precipitation, the supernatant was directly (unfiltered) injected onto the LC column (retention time approximately 4.3 min) for analysis. Interday and intraday accuracy and precision were assessed from the relative recoveries (observed concentration in percent of the nominal value) of spiked samples analyzed on three different days. The lower limit of quantitation (LLOQ) was 0.0679 ng/mL in human and minipig using a plasma sample volume of 0.08 mL. The method was fast, specific, and exhibited ruggedness. Furthermore, the use of turbulent flow chromatography (TurboFlow LC/MS/MS) coupled to mass spectrometry for direct analysis of terbinafine in plasma is discussed. The technique allowed direct introduction of plasma with satisfactory chromatographic peak shape and increased throughput.


Subject(s)
Antifungal Agents/blood , Chromatography, High Pressure Liquid , Mass Spectrometry/methods , Naphthalenes/blood , Swine, Miniature/blood , Animals , Antifungal Agents/pharmacokinetics , Calibration , Chemical Precipitation , Humans , Naphthalenes/pharmacokinetics , Quality Control , Reference Standards , Sensitivity and Specificity , Species Specificity , Swine , Terbinafine
14.
Biopharm Drug Dispos ; 20(2): 69-75, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10206321

ABSTRACT

The present study is concerned with the absorption and disposition of a tripeptoid (N-substituted glycine derivative) and a tetrapeptide in the rat. The two compounds have similar backbone structures but differ with respect to the presence or absence of peptide bond. [3H]tripeptoid and [3H]tetrapeptide were administered orally (30 mg kg(-1)) and intravenously (i.v.) (30 or 3 mg kg(-1)) to Sprague Dawley rats. Blood, urine and feces were collected at designated times for radioactivity and parent drug analysis. The intestinal absorptive clearances of the tripeptoid and tetrapeptide were studied using an in situ rat intestinal perfusion model. The octanol/water partition coefficient of these two compounds was also determined. The results showed that the peptoid and peptide have similar absorptive clearance and octanol/water partitioning, but different in vivo absorption and disposition characteristics. The absorptive clearances of the tripeptoid and tetrapeptide were 6.7 and 4.8 x 10(-4) mL min(-1) cm(-1), respectively, and the corresponding octanol/water partition coefficients were 0.39 and 0.30. The extent of oral absorption of the tripeptoid was only 3-8%, consistent with its low absorptive clearance. In contrast, the apparent absorption of the tetrapeptide was > 75% of the radioactive dose. The peptide was completely metabolized within 2 h after an i.v. dose, whereas the peptoid was stable in blood and was primarily eliminated in feces as intact drug. In conclusion, the difference in in vivo absorption and disposition between the peptoid and peptide was apparently due to the presence or absence of a peptide bond. The tetrapeptide was subject to rapid metabolism in the body. Its relatively high absorption appeared to represent the absorption of metabolized radioactive fragments. The peptoid appears to have advantages over the peptide in term of metabolic stability, but its low oral absorption and rapid biliary excretion present additional challenges in the selection of an optimal drug candidate.


Subject(s)
Glycine/analogs & derivatives , Glycine/pharmacokinetics , Oligopeptides/pharmacokinetics , Administration, Oral , Animals , Glycine/administration & dosage , Intestinal Absorption , Male , Oligopeptides/administration & dosage , Peptoids , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship , Tissue Distribution , Tritium
15.
Pharm Res ; 15(10): 1614-20, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9794506

ABSTRACT

PURPOSE: SDZ ENA 713 (rivastigmine) is an acetylcholinesterase inhibitor intended for therapeutic use in Alzheimer's disease. The present study compared the pharmacokinetics of [14C]SDZ ENA 713 after intravenous, oral, and dermal administration to male minipigs, and also examined the effects of dose level and skin abrasion on transdermal absorption. METHODS: Four groups of 3 minipigs each received a single intravenous (0.1 mg/kg), single oral (1.0 mg/kg), or topical doses of 18 mg or 54 mg of [14C]SDZ ENA 713. Topical doses were administered as dermal patches on two occasions 10 days apart. On Study Day 1, test patches were applied to a virgin skin site. Placebo patches were applied to a separate skin site and were replaced daily during Days 1-10. On Study Day 11, test patches were applied to the site on which the placebo patches had been previously applied. After each dose, serial blood and quantitative urine and feces were collected at designated intervals for 7 days. Concentrations of radioactivity, parent drug, and metabolite ZNS 114-666 were measured in whole blood. Radioactivity was also determined in excreta, skin application sites (at study termination), and on used dermal patches (at 24 hr after application). RESULTS: Oral doses of [14C]SDZ ENA 713 were rapidly (tmax = 0.83 hr) and efficiently (ca. 93%) absorbed, although the bioavailability of the parent drug was low, ca. 0.5%, apparently due to extensive first-pass metabolism. Radioactivity was excreted mainly in the urine (approximately 90%) with a half-life of 56 hr, slightly longer than that observed after an intravenous dose, 46 hr. After dermal administration of [14C]SDZ ENA 713 to a virgin skin site, absorption was 8% at both dose levels investigated. Following daily application of placebo patches for 10 days, absorption from a [14C]SDZ ENA 713 dermal patch increased by approximately twofold, 17% and 19% of the 18 mg and 54 mg doses, respectively. The increase is possibly due to hydration or abrasion of the skin as a result of repeated application and removal of the adhesive patches. Whereas total absorption from the dermal dose was smaller than that from the oral dose, essentially all of the absorbed drug via the dermal route reached the systemic circulation intact, thus yielding a SDZ ENA 713 bioavailability 20-40 times greater than that of the oral dose. Metabolite ZNS 114-666 was rapidly formed and accounted for <4% of total drug-related material in the systemic circulation. CONCLUSIONS: Dermal administration in minipigs provided a markedly greater bioavailability of SDZ ENA 713 than the oral route. The extent of absorption was independent of dose within the range tested, and appeared to be enhanced by hydration or abrasion of the skin application site.


Subject(s)
Carbamates/pharmacokinetics , Cholinesterase Inhibitors/pharmacokinetics , Phenylcarbamates , Administration, Cutaneous , Administration, Oral , Animals , Carbamates/administration & dosage , Injections, Intravenous , Male , Rivastigmine , Swine , Swine, Miniature
16.
Biopharm Drug Dispos ; 19(5): 285-90, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9673779

ABSTRACT

The disposition of SDZ ENA 713, indicated for the treatment of Alzheimer's disease, was studied in non-pregnant, pregnant, and lactating New Zealand white rabbits. 3H-SDZ ENA 713 was administered as single oral or intravenous dose (1.09 mg kg-1) and as multiple oral doses (1.09 mg kg-1) daily for 7 days. Serial blood and milk samples, selected tissues and excreta samples were collected. Radioactivity was determined in all biological samples by liquid scintillation counting. Concentrations of unchanged SDZ ENA 713 and its phenolic metabolite, ZNS 114-666, were measured by GC-MS. Pharmacokinetic parameters were determined by model independent methods. The rate and onset of absorption were rapid (tmax 1.3 +/- 0.58 h) and the extent of absorption was essentially complete. Concentrations of SDZ ENA 713 were below the limit of quantification (0.98 ng mL-1) after oral administration. Following intravenous administration, SDZ ENA 713 was extensively distributed (Vss = 3.1 L kg-1) and rapidly cleared (Cl = 2.7 L h-1 kg-1). The radioactivity was primarily excreted via the kidneys (86% of dose). In pregnant rabbits receiving multiple oral doses, the fetus to placentae tissue ratio of radioactivity averaged 0.5. Passage of radioactivity from blood into milk was rapid (tmax = 2 h) and the milk:blood AUC ratio of radioactivity averaged 1.5. No unchanged SDZ ENA 713 was detected in the milk samples; however, there were measurable concentrations of the phenolic metabolite (Cmax = 82.9 ng mL-1). The milk to blood ratio of the phenolic metabolite averaged 2.3. In conclusion, SDZ ENA 713 underwent extensive presystemic metabolism following oral administration. There was moderate transfer of drug-related materials across the placenta. Projecting the rabbit data to humans, it is suggested that nursing neonates would not be exposed to unchanged SDZ ENA 713 following oral doses to nursing mothers.


Subject(s)
Carbamates/pharmacokinetics , Cholinesterase Inhibitors/pharmacokinetics , Phenylcarbamates , Animals , Female , Milk/metabolism , Placenta/metabolism , Pregnancy , Rabbits , Rivastigmine , Tissue Distribution
18.
Biopharm Drug Dispos ; 19(9): 571-5, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9872338

ABSTRACT

This study was conducted to determine the uptake of dihydroergotamine (DHE) into the brain after intravenous and intranasal administration in rats. Eight anesthetized rats received either an intravenous (i.v.) or two successive intranasal (i.n.) doses of tritium labeled dihydroergotamine (3H-DHE) with 14C-inulin as a non-BBB (blood-brain barrier) permeable marker. Radioactivity concentrations in plasma were determined at designated times within 30 min postdose, and in blood and seven brain regions (olfactory bulb, frontal cortex, parietal cortex, occipital cortex, cerebellum, mid-brain areas, and brain stem) at 30 min. The plasma-to-brain permeability*area product (PeA) following an i.v. dose was calculated based on the 30-min brain tissue concentration and the area under the plasma concentration-time curve (AUC0-30 min, i.v.) assuming unidirectional transport from plasma to brain. Direct transport from nasal cavity to brain was assessed based on the amount of radioactivity in brain determined experimentally and predicted based on plasma AUC0-30 min, i.n. and PeA obtained from i.v. data. Following an i.v. dose, DHE distributed into the brain with a brain-to-plasma concentration ratio of approximately 5% at 30 min postdose. The PeA value of DHE ranged from 8.6 x 10(-4) to 37.5 x 10(-4) mL min(-1) g(-1) in different brain regions. Following i.n. doses the experimentally determined concentration in olfactory bulb was approximately 51 times, and in other regions three to seven times, greater than predicted values based only on PeA and plasma AUC, suggesting a direct transport pathway from the nasal cavity to the brain. As a result, the brain tissue concentrations at 30 min were similar to (0.31-1.04 times) those following an i.v. dose except for the olfactory bulb, in which the concentration was approximately four times greater than that following an i.v. dose. In conclusion, 3H-DHE penetrated the BBB following intravenous administration. Following i.n. doses, 3H-DHE was able to enter the brain directly from the nasal cavity, with the olfactory bulb being a part of the direct passage from nasal cavity to brain.


Subject(s)
Brain/metabolism , Dihydroergotamine/pharmacokinetics , Vasoconstrictor Agents/pharmacokinetics , Administration, Intranasal , Animals , Injections, Intravenous , Male , Rats , Rats, Sprague-Dawley , Tissue Distribution
19.
Pharm Res ; 14(11): 1563-7, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9434275

ABSTRACT

PURPOSE: A permeability-index approach was developed and used to study the transport of D-glucose in the jejunum and ileum of rats. METHODS: The effective permeability coefficient (Pe) of [3H]D-glucose and [14C]antipyrine (an internal standard) in jejunum and ileum of four rats was determined using an in situ rat intestinal perfusion technique. The permeability ratio of the test compound (D-glucose) to the internal standard was defined as the permeability-index (P(i)), which was mathematically independent of the length and surface area of the intestinal segment perfused. Using this approach, the transport of [3H]D-glucose in jejunum and ileum of eight animals was investigated at concentrations ranging from 1 to 300 mM. The tissue/perfusate distribution of [3H]D-glucose and [14C]antipyrine at steady state was also determined. RESULTS: The variability (%CV) in P(i) of D-glucose was only approximately 5%, compared with 23-36% in Pe values of D-glucose or antipyrine alone. The permeability and tissue distribution of [14C]antipyrine were unaffected by the presence of D-glucose. In contrast, the permeability and tissue distribution of [3H]D-glucose were concentration-dependent in both jejunum and ileum. The transport of D-glucose was studied assuming that the transport was mediated by a carrier (with maximum flux, Vmax and dissociation constant, Km) as well as by non-saturable transport (Pd). The maximum transport capacity for D-glucose in jejunum (0.522 mumole/min/cm2) was twice that in ileum (0.199 mumole/min/cm2), but the affinity (1/Km) was less than half of that in ileum (1/(48.2 mumole/mL) vs. 1/(21.4 mumole/mL)), rendering a similar active transport efficiency (Vmax/Km) in these two regions. The non-saturable permeability (Pd) in jejunum (44.6 x 10(-4) cm/min) was approximately twice that in ileum (20.4 x 10(-4) cm/min). CONCLUSIONS: The permeability-index approach yielded parameters with reduced variability by eliminating potential imprecisions in length and surface area measurements of the intestinal segments perfused. D-glucose was transported via carrier-mediated systems in both jejunum and ileum, with different transport capacity and affinity in these two regions.


Subject(s)
Antipyrine/pharmacokinetics , Cell Membrane Permeability , Glucose/pharmacokinetics , Intestinal Absorption , Perfusion/methods , Animals , Carbon Radioisotopes/metabolism , Ileum/metabolism , Jejunum/metabolism , Rats , Tissue Distribution , Tritium/metabolism
20.
Pharm Res ; 13(7): 1105-8, 1996 Jul.
Article in English | MEDLINE | ID: mdl-8842053

ABSTRACT

PURPOSE: Sparse sampling in rodent toxicokinetics usually involves the collection of a single blood sample on a given study day from each animal in a treatment group. The samples are allocated to different time points, often allowing some replicates, and statistical inferences are then made about the concentration-time behavior of the test compound. The present study compared the results of one such analysis with those obtained from serial sampling as might be applied using satellite animals. METHODS: Ten rats each received a single oral dose of tritium-labeled compound X. Blood concentrations in each rat at 10 time points post-dose were determined by liquid scintillation counting. Individual peak concentrations of blood radioactivity (Cmax) and peak times (tmax) were recorded, and area-under-curve (AUC) values were calculated by trapezoidal rule. The mean AUC and Cmax of all 10 animals over all 10 time points, referred to as AUCtrue and Cmax,true, were used as points of reference. These values were then estimated using subsets of the data that simulated satellite-animal or sparse-sampling designs. First, several different sampling schedules of 5 bleeding times were stimulated by taking subsets of the full data set. For analysis using satellite animals, serial blood concentrations from subsets of 3 or 4 rats were used to calculate point and confidence-interval estimates of AUCtrue and Cmax,true by standard methods; all possible subsets of 3 or 4 of the 10 rats were considered. For sparse data analysis, a single concentration from each of the 10 rats was used to calculate both point and confidence-interval estimates of AUCtrue by the Bailer-Satterthwaite method, and point estimates of Cmax,true, according to several different designs of replication. Animals were randomly assigned to time points, and 1000 of over 50000 possible combinations were evaluated for each bleeding schedule. The average percent absolute errors of the point estimates were computed and, for the 95% confidence intervals, average widths were determined. RESULTS: For point estimates of AUCtrue, sparse sampling yielded average percent absolute errors of 7-13%. Percent errors for 3 and 4 satellite animals were 6-12% and 5-10%, respectively. For 95% confidence intervals, sparse sampling yielded widths of 24-90% of AUCtrue, whereas for 3 and 4 satellite animals widths were 37-50% and 24-34%, respectively. For Cmax,true point estimates from sparse-sampling and satellite-animal approaches had average percent absolute errors of 5-12% and 3-8%, respectively. The confidence-interval widths for Cmax,true from the satellite-animal approach were 15-24% of Cmax,true, but coverage did not achieve the nominal 95% for some choices of sampling times. CONCLUSIONS: By using proper study designs, one can limit the number of samples and the amount of blood drawn so as not to affect the animals' health status, yet still achieve the customary pharmacokinetic objectives in a toxicity study.


Subject(s)
Pharmacokinetics , Toxicity Tests/methods , Animals , Cholinesterase Inhibitors/administration & dosage , Cholinesterase Inhibitors/blood , Cholinesterase Inhibitors/pharmacokinetics , Male , Rats , Rats, Sprague-Dawley , Tritium
SELECTION OF CITATIONS
SEARCH DETAIL
...